Factor X Inhibitors
1 drugsAbout Factor X
Factor X is a serine protease essential for the coagulation cascade, converting prothrombin to thrombin to form blood clots.
Factor X is a therapeutic target due to its role in coagulation, though no direct genetic evidence currently links it to specific diseases.
One FDA-approved drug, HEMLIBRA, targets Factor X as an antibody therapeutic in the 'Other' therapeutic area.
Top Factor X Drugs
Roche is the only company with an approved drug targeting Factor X.
The market is highly concentrated, suggesting high barriers to entry for new competitors.
Factor X Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Factor X, using antibody modality.
Exploring alternative modalities like small molecules could provide a competitive advantage.
Factor X Clinical Trials 28 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Factor X. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 | 100% |
| Phase 2 | 4 | 1 | 0 | 3 | 100% |
| Phase 3 | 15 | 7 | 5 | 3 | 58% |
| Phase 4 | 7 | 0 | 3 | 4 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved Factor X drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Factor X. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Factor X Drug Approval Timeline (2017 - 2017)
The first and only drug, HEMLIBRA, was approved in 2017.
The approval timeline suggests the target is not saturated, with potential for further development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Factor X. A trial counts if an approved drug acting on Factor X is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.